Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model

Rashade A H Haynes, Evan Ware, Christopher Premanandan, Bevin Zimmerman, Lianbo Yu, Andrew J. Phipps, Michael Dale Lairmore

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia and several lymphocyte-mediated inflammatory diseases. Persistent HTLV-1 infection is determined by a balance between host immune responses and virus spread. Immunomodulatory therapy involving HTLV-1-infected patients occurs in a variety of clinical settings. Knowledge of how these treatments influence host-virus relationships is not understood. In this study, we examined the effects of cyclosporine A (CsA)-induced immune suppression during early infection of HTLV-1. Twenty-four New Zealand white rabbits were split into 4 groups. Three groups were treated with either 10 or 20 mg/kg CsA or saline before infection. The fourth group was treated with 20 mg/kg CsA 1 week after infection. Immune suppression, plasma CsA concentration, ex vivo lymphocyte HTLV-1 p19 production, anti-HTLV-1 serologic responses, and proviral load levels were measured during infection. Our data indicated that CsA treatment before HTLV-1 infection enhanced early viral expression compared with untreated HTLV-1-infected rabbits, and altered long-term viral expression parameters. However, CsA treatment 1 week after infection diminished HTLV-1 expression throughout the 10-week study course. Collectively, these data indicate immunologic control is a key determinant of early HTLV-1 spread and have important implications for therapeutic intervention during HTLV-1-associated diseases.

Original languageEnglish (US)
Pages (from-to)815-823
Number of pages9
JournalBlood
Volume115
Issue number4
DOIs
StatePublished - Jan 28 2010
Externally publishedYes

Fingerprint

Human T-lymphotropic virus 1
Virus Diseases
Viruses
Cyclosporine
Rabbits
Infection
Lymphocytes
Adult T Cell Leukemia Lymphoma
Immunomodulation
Therapeutics
T-cells

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Haynes, R. A. H., Ware, E., Premanandan, C., Zimmerman, B., Yu, L., Phipps, A. J., & Lairmore, M. D. (2010). Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. Blood, 115(4), 815-823. https://doi.org/10.1182/blood-2009-07-230912

Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. / Haynes, Rashade A H; Ware, Evan; Premanandan, Christopher; Zimmerman, Bevin; Yu, Lianbo; Phipps, Andrew J.; Lairmore, Michael Dale.

In: Blood, Vol. 115, No. 4, 28.01.2010, p. 815-823.

Research output: Contribution to journalArticle

Haynes, RAH, Ware, E, Premanandan, C, Zimmerman, B, Yu, L, Phipps, AJ & Lairmore, MD 2010, 'Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model', Blood, vol. 115, no. 4, pp. 815-823. https://doi.org/10.1182/blood-2009-07-230912
Haynes RAH, Ware E, Premanandan C, Zimmerman B, Yu L, Phipps AJ et al. Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. Blood. 2010 Jan 28;115(4):815-823. https://doi.org/10.1182/blood-2009-07-230912
Haynes, Rashade A H ; Ware, Evan ; Premanandan, Christopher ; Zimmerman, Bevin ; Yu, Lianbo ; Phipps, Andrew J. ; Lairmore, Michael Dale. / Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model. In: Blood. 2010 ; Vol. 115, No. 4. pp. 815-823.
@article{4c32d13de5674df7bd0a3a1c0528de52,
title = "Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model",
abstract = "Human T-lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia and several lymphocyte-mediated inflammatory diseases. Persistent HTLV-1 infection is determined by a balance between host immune responses and virus spread. Immunomodulatory therapy involving HTLV-1-infected patients occurs in a variety of clinical settings. Knowledge of how these treatments influence host-virus relationships is not understood. In this study, we examined the effects of cyclosporine A (CsA)-induced immune suppression during early infection of HTLV-1. Twenty-four New Zealand white rabbits were split into 4 groups. Three groups were treated with either 10 or 20 mg/kg CsA or saline before infection. The fourth group was treated with 20 mg/kg CsA 1 week after infection. Immune suppression, plasma CsA concentration, ex vivo lymphocyte HTLV-1 p19 production, anti-HTLV-1 serologic responses, and proviral load levels were measured during infection. Our data indicated that CsA treatment before HTLV-1 infection enhanced early viral expression compared with untreated HTLV-1-infected rabbits, and altered long-term viral expression parameters. However, CsA treatment 1 week after infection diminished HTLV-1 expression throughout the 10-week study course. Collectively, these data indicate immunologic control is a key determinant of early HTLV-1 spread and have important implications for therapeutic intervention during HTLV-1-associated diseases.",
author = "Haynes, {Rashade A H} and Evan Ware and Christopher Premanandan and Bevin Zimmerman and Lianbo Yu and Phipps, {Andrew J.} and Lairmore, {Michael Dale}",
year = "2010",
month = "1",
day = "28",
doi = "10.1182/blood-2009-07-230912",
language = "English (US)",
volume = "115",
pages = "815--823",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model

AU - Haynes, Rashade A H

AU - Ware, Evan

AU - Premanandan, Christopher

AU - Zimmerman, Bevin

AU - Yu, Lianbo

AU - Phipps, Andrew J.

AU - Lairmore, Michael Dale

PY - 2010/1/28

Y1 - 2010/1/28

N2 - Human T-lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia and several lymphocyte-mediated inflammatory diseases. Persistent HTLV-1 infection is determined by a balance between host immune responses and virus spread. Immunomodulatory therapy involving HTLV-1-infected patients occurs in a variety of clinical settings. Knowledge of how these treatments influence host-virus relationships is not understood. In this study, we examined the effects of cyclosporine A (CsA)-induced immune suppression during early infection of HTLV-1. Twenty-four New Zealand white rabbits were split into 4 groups. Three groups were treated with either 10 or 20 mg/kg CsA or saline before infection. The fourth group was treated with 20 mg/kg CsA 1 week after infection. Immune suppression, plasma CsA concentration, ex vivo lymphocyte HTLV-1 p19 production, anti-HTLV-1 serologic responses, and proviral load levels were measured during infection. Our data indicated that CsA treatment before HTLV-1 infection enhanced early viral expression compared with untreated HTLV-1-infected rabbits, and altered long-term viral expression parameters. However, CsA treatment 1 week after infection diminished HTLV-1 expression throughout the 10-week study course. Collectively, these data indicate immunologic control is a key determinant of early HTLV-1 spread and have important implications for therapeutic intervention during HTLV-1-associated diseases.

AB - Human T-lymphotropic virus type 1 (HTLV-1) infection causes adult T-cell leukemia and several lymphocyte-mediated inflammatory diseases. Persistent HTLV-1 infection is determined by a balance between host immune responses and virus spread. Immunomodulatory therapy involving HTLV-1-infected patients occurs in a variety of clinical settings. Knowledge of how these treatments influence host-virus relationships is not understood. In this study, we examined the effects of cyclosporine A (CsA)-induced immune suppression during early infection of HTLV-1. Twenty-four New Zealand white rabbits were split into 4 groups. Three groups were treated with either 10 or 20 mg/kg CsA or saline before infection. The fourth group was treated with 20 mg/kg CsA 1 week after infection. Immune suppression, plasma CsA concentration, ex vivo lymphocyte HTLV-1 p19 production, anti-HTLV-1 serologic responses, and proviral load levels were measured during infection. Our data indicated that CsA treatment before HTLV-1 infection enhanced early viral expression compared with untreated HTLV-1-infected rabbits, and altered long-term viral expression parameters. However, CsA treatment 1 week after infection diminished HTLV-1 expression throughout the 10-week study course. Collectively, these data indicate immunologic control is a key determinant of early HTLV-1 spread and have important implications for therapeutic intervention during HTLV-1-associated diseases.

UR - http://www.scopus.com/inward/record.url?scp=77949329047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949329047&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-230912

DO - 10.1182/blood-2009-07-230912

M3 - Article

C2 - 19965683

AN - SCOPUS:77949329047

VL - 115

SP - 815

EP - 823

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -